Friday, April 10, 2026 6:00:28 AM
Organon Shares Jump on Reports of Potential $12 Billion Bid from Sun Pharma
April 10, 2026 5:52 AM
IH Market News
Shares of Organon (NYSE:OGN) rose 8.4% to $7.49 in premarket trading on Friday after reports indicated that India’s Sun Pharmaceutical Industries is preparing to move forward with a $12 billion binding offer for the company.
According to the Economic Times, Sun Pharma has spent the past three months conducting in-depth due diligence and is now working to finalize its financing arrangements ahead of submitting a formal bid in the coming weeks, citing sources familiar with the situation.
Organon, a company focused on women’s health, did not immediately comment when contacted outside of normal business hours.
Original: Organon Shares Jump on Reports of Potential $12 Billion Bid from Sun Pharma
Recent OGN News
- Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis • Business Wire • 04/15/2026 11:30:00 AM
- Organon Shares Jump on Reports of Potential $12 Billion Bid from Sun Pharma • IH Market News • 04/10/2026 09:52:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:26:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:11:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:06:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:15:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:12:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:11:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:10:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:08:06 PM
- Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age • Business Wire • 03/27/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 12:02:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 12:00:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:58:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 11:56:43 PM
- New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis • Business Wire • 02/27/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 09:24:45 PM
- Organon conclut un accord pour obtenir la licence de MIUDELLA®, le dispositif intra-utérin sans hormones de Sebela Pharmaceuticals • Business Wire • 02/24/2026 01:55:00 PM
- オルガノン、セベラ・ファーマシューティカルズのホルモンフリー子宮内避妊具「MIUDELLA ® 」のライセンス契約を 締結 • Business Wire • 02/23/2026 09:36:00 PM
- Organon schließt Lizenzvereinbarung für MIUDELLA®, das hormonfreie Intrauterinpessar von Sebela Pharmaceuticals • Business Wire • 02/23/2026 08:52:00 PM
- Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device • Business Wire • 02/23/2026 12:30:00 PM
- Organon climbs 6% after audit clears company of wrongdoing • IH Market News • 02/20/2026 01:28:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 12:30:42 PM
